Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Conventional Treatment in Refractory Nephrotic Syndrome
NCT05553496Phase 3Unknown
- Sponsor
- Ain Shams University
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of rituximab in nephrotic syndrome, sponsored by Ain Shams University. Status: unknown.
02
Drugs
rituximab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT05553496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553496.